Invivyd, Inc. · NASDAQ:IVVD
Invivyd — Investor Presentation (August 2025)
24 slides from Invivyd's investor presentation, Aug 14, 2025
Slide 1: Corporate Deck August 2025
Exhibit 99.3 Corporate Deck August 2025 © 2025 Invivyd, Inc. Invivyd®, the Invivyd logo, Pemgarda® and the Ribbon logo are registered trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners. 1
Slide 2: Cautionary Note Regarding Forward-Looking Statements
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words
Slide 3: Agenda
AGENDA u COVID-19 Landscape and Opportunity Next Steps 3
Slide 4: COVID-19 Is the Most Damaging and Deadly of Prevalent Respiratory Viruses
COVID-19 IS THE MOST DAMAGING AND DEADLY OF PREVALENT RESPIRATORY VIRUSES COVID-19 is the leading cause of hospitalizations and death from respiratory viruses in the U.S. (2023-2024 data)* 1 Hospitalizations * Deaths* 2 COVID-19 460,000 45,200 3 INFLUENZA 272,000 9,900 4† RSV 179,000 ~6,000–10,000 C
Slide 5: COVID-19: An Ongoing Health Crisis Still Making Headlines Year After Year
COVID-”19”: AN ONGOING HEALTH CRISIS STILL MAKING HEADLINES YEAR AFTER YEAR 2025 2021 2022–2023 2024 COVID-19 cases are rising in these states amid summer wave, CDC data shows January 10, 2024 July 21, 2025 July 2, 2021 August 31, 2022 June 11, 2021 Why are more than 300 people in the US still dying
Slide 6: The Impact of COVID-19 Appears to Reach Past Acute Infection
THE IMPACT OF COVID-19 APPEARS TO REACH PAST ACUTE INFECTION Beginning in 2021, the rate of American disability appears COVID-19 illness and restrictions appear to have a significant to increase. We believe COVID-19 could contribute to this impact on disruptions to cancer care. trend. References: 1.
Slide 7: Agenda
AGENDA u COVID-19 u Landscape and Opportunity Next Steps 7
Slide 8: We Believe COVID-19 Vaccines Do Not Provide Sufficient Protection
WE BELIEVE COVID-19 VACCINES DO NOT PROVIDE SUFFICIENT PROTECTION 1 Adults≥18 years by 2023–2024 COVID-19 Vaccine immunocompromise/ Adjusted Vaccine Effectiveness Against Hospitalization The 2023-24 Vaccine vaccination status/days since dose [%, (95% Confidence Interval)] Effectiveness (VE) estimate
Slide 9: Monoclonal Antibodies Have Been Shown to Robustly Protect People From COVID-19
MONOCLONAL ANTIBODIES HAVE BEEN SHOWN TO ROBUSTLY PROTECT PEOPLE FROM GETTING SICK WITH COVID-19 1 3,4 Tixagevimab+cilgavimab Adintrevimab * Pemivibart * 2 (“Evusheld”) * PROVENT 71% reduction* 84-94% reduction* 77% reduction* in risk of in risk of in risk of symptomatic COVID-19 symptomatic COVID-1
Slide 10: Our Proprietary Platform Is Designed to Address Evolution and Broad Medical Need
OUR PROPRIETARY PLATFORM IS DESIGNED TO ADDRESS EVOLUTION AND BROAD MEDICAL NEED Rapid mAb Engineering Rapid, Compact Studies Commercial Opportunity • Multiple profiles anticipated to be generated for specific • Privileged epitopes • Compact clinical programs to molecules and use cases • Rapid affin
Slide 11: Pipeline
PIPELINE Potential expansion beyond 2026-2027: HBV/HDV and Lyme HBV=hepatitis B virus; HDV=hepatitis D virus; RSV=respiratory syncytial virus. 11 All monoclonal antibodies listed are investigational therapies and have not been approved for use by any regulatory authority.
Slide 12: PEMGARDA Authorized via EUA for Prevention of COVID-19
PEMGARDA AUTHORIZED VIA EUA FOR THE PREVENTION OF COVID-19 FOR CERTAIN IMMUNOCOMPROMISED PERSONS PEMGARDA has not been approved but has been authorized for emergency use by the FDA under an emergency use authorization (EUA), for pre-exposure prophylaxis of COVID-19 in certain adults and adolescents
Slide 13: VYD2311 Designed to Be a High Potency, Long Half Life Monoclonal Antibody
VYD2311 DESIGNED TO BE A HIGH POTENCY, LONG HALF LIFE MONOCLONAL ANTIBODY FOR COVID-19 Our next-generation mAb, VYD2311, designed to improve upon biophysical properties (potency, half-life) Development: Awaiting Pivotal Trial; low dose IM dosing possible • First-in-human (FIH) trial complete • Obser
Slide 14: Clinical Data Allows Rational Dose Selection; VYD2311 Pivotal Protocol Under Development
CLINICAL DATA ALLOWS RATIONAL DOSE SELECTION; VYD2311 PIVOTAL PROTOCOL UNDER DEVELOPMENT 1 2 Yalcin et al, medRxiv Schmidt et al, Science Translational Medicine References: 1. Yalcin, et al., A statistical immune correlates of protection model for predicting efficacy from neutralizing antibody titer
Slide 15: Our Goal: The Beginning of a New Category
OUR GOAL: THE BEGINNING OF A NEW CATEGORY PEMGARDA VYD2311 Target Product Profile Status EUA BLA Population Mod / Severe IC Anyone Delivery High dose IV, multi-hour follow up Low dose IM (“boop”) at pharmacy / clinic Indication / Endpoint Immunobridge “Protection from COVID” Protection 84-94% Simila
Slide 16: Goal: Provide Americans With a Choice for COVID-19 Protection
GOAL: PROVIDE AMERICANS WITH A CHOICE FOR COVID-19 PROTECTION Monoclonal Antibody: COVID-19 Vaccine VYD2311 • Reactogenic • Not a vaccine • Myocarditis risk • Immunologically silent • Short duration of protection (weeks) • Natural, supplemental protection • Modest efficacy • Long duration of protect
Slide 17: Invivyd Is Actively Driving Toward a Seismic Shift
INVIVYD IS ACTIVELY DRIVING TOWARD A SEISMIC SHIFT Rapid, efficient pathway unlocked to BLA submission for VYD2311 monoclonal antibody for COVID-19 prevention Invivyd makes minimally evolved molecular entity (“MEME”) monoclonal antibodies that are designed to minimize risk and have potential to enab
Slide 18: Respiratory Syncytial Virus (RSV) Discovery
RESPIRATORY SYNCYTIAL VIRUS (RSV) DISCOVERY • Well-developed mAb medical category devoted to Fusion Protein Trimer prevention of RSV in neonates and children <24 months • Current key molecules: o Pavilizumab (1998) - AstraZeneca o Nirsevimab (2023) - Sanofi o Clesrovimab (2025 expected) - Merck • Op
Slide 19: Measles (Rubeola) Virus Discovery
MEASLES (RUBEOLA) VIRUS DISCOVERY • Despite highly effective vaccines, U.S. herd 2 Measles (MeV) Spectrum of Clinical Disease immunity against measles is at risk Multiple Points of Intervention • Multiple circulating strains make measles an attractive target for Invivyd technology • mAb envisioned t
Slide 20: Agenda
AGENDA u COVID-19 u Landscape and Opportunity u Next Steps 20
Slide 21: Aiming for a Disruption of COVID-19 Landscape While Advancing Select Pipeline Opportunities
AIMING FOR A DISRUPTION OF COVID-19 LANDSCAPE WHILE ADVANCING SELECT PIPELINE OPPORTUNITIES Design and align on pivotal clinical trial plan for PEMGARDA base business growing; informing pediatrics: potential for high-yield commercial commercial planning and supporting market focus (blockbuster Beyfo
Slide 22: What Do We Envision Beyond 2026-2027?
WHAT DO WE ENVISION BEYOND 2026-2027? VYD25XY Series mAbs Expansion Additional diseases and indications that Option for lower dose IM; align with overall strategy subcutaneous; plan for similar rapid consideration development • RSV (aim for better fast-follower to • Home / on-demand administration.
Slide 23: Enable Shift in Infectious Disease Prevention to Rebuild Trust in American Healthcare
ENABLE SHIFT IN INFECTIOUS DISEASE PREVENTION TO BEGIN TO REBUILD TRUST IN AMERICAN HEALTHCARE THROUGH CHOICE AND NATURAL IMMUNE SUPPORT Move Away From: Move Toward: • Addressing public health crisis of distrust in • COVID-19 vaccine-only approach to American healthcare prevention • Individual choic
Slide 24: Financials
FINANCIALS • Q2 2025 PEMGARDA® (pemivibart) net product revenue of $11.8 million • Continued execution of financial discipline and reduction of operating expenses – $26.2 million in Q2 2025 vs. $27.4 million in Q1 2025 and $32.3 million in Q4 2024 • Ended Q2 2025 with approximately $34.9 million in